hackint0sh/New-Dataset huggingface dataset:
This study will adopt a 3+3 design and include two predefined dose groups of palbociclib: 100mg QD, 125mg QD. Initially, Tislelizumab, 200 mg administered by intravenous infusion on Day 1 of each 21-day will be administered in combination. The trial will use the first cycle (28 days) as the observation period for tolerability, observing and evaluating the occurrence of DLTs after medication and determining the maximum tolerated dose/maximum administered dose (MTD/MAD) and recommended phase 2 dose (RP2D) of the combination therapy (30 patients) .
This study provide further evidence for improving the efficacy of neoadjuvant treatment forplatinum-refractory cT2-4aN0M0 bladder urothelial carcinoma and to offer new options for precision treatment of bladder cancer. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Tislelizumab combined with two predefined dose groups of palbociclib name: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. measure: Phase I: the safety dose of the combination of Tislelizumab and palbociclib measure: Phase II: Pathological complete response rate(pCR) measure: Pathological Downstaging(pDS) measure: Event-free survival (EFS) measure: overall survival (OS) measure: Safety and AE measure: Biomarker Endpoint Analyses sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang Hospital, Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Fan Wu, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Sun Yat-sen Memorial Hospital status: RECRUITING city: Guangzhou state: Guangdong country: China name: Wenlong Zhong, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: The First Affiliated Hospital of Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Junxin Chen, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: The Third Affiliated Hospital of Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Yun Luo, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Zhujiang Hospital of Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Ebai Xu, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology status: RECRUITING city: Wuhan state: Hubei country: China name: Zheng Liu, Ph.D role: CONTACT lat: 30.58333 lon: 114.26667 facility: Hunan Cancer Hospital status: RECRUITING city: Changsha state: Hunan country: China name: Yu Xie, Ph.D role: CONTACT lat: 28.19874 lon: 112.97087 facility: Xiangya Hospital, Central South University status: RECRUITING city: Changsha state: Hunan country: China name: Xiongbing Zu, Ph.D role: CONTACT lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06364943 id: 202400020B0 briefTitle: Tear Ferning Test for Dry Eye Diagnosis overallStatus: RECRUITING date: 2024-04-05 date: 2025-01-05 date: 2025-04-04 date: 2024-04-15 date: 2024-04-15 name: Chung Shan Medical University class: OTHER briefSummary: Application of tear ferning test for clinical dry eye diagnosis conditions: Dry Eye Syndromes studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 20 type: ESTIMATED name: with/without dry eye syndrome measure: Schirmer's test measure: Tear film breakup time measure: Ocular surface health evaluate measure: Ocular surface disease index measure: Intraocular pressure sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jen-Ai Hospital status: RECRUITING city: Taichung, zip: 412 country: Taiwan name: SHU-YAN PENG, Master role: CONTACT phone: 886-933-854862 lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06364930 id: SGLT2i_HBV Study briefTitle: SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus overallStatus: RECRUITING date: 2024-03-26 date: 2030-10-31 date: 2031-03-30 date: 2024-04-15 date: 2024-04-15 name: Chinese University of Hong Kong class: OTHER briefSummary: This is a five-year, double blinded, randomised trial of dapagliflozin versus placebo in patients with chronic hepatitis B and DM or IFG complicated with compensated advanced chronic liver disease (cACLD). 412 subjects will be recruited. Subject will be randomly assigned to receive dapagliflozin 10mg daily or dapagliflozin placebo one tablet daily for up to 5 years. After randomization, subject will be followed up at month 3, month 6 and then 6-monthly until 60 months (follow up ± 4 weeks from scheduled clinic visit is allowed). At each visit, drug compliance, physical examination, observed or reported adverse events will be assessed. 10ml of blood will be taken at each visit and transient elastography to assess fibrosis regression will be performed at 60th month or at withdrawal visit. You are discouraged to use (pegylated)-interferon, any other NA including lamivudine, adefovir, and telbivudine, another SGLT2i Empagliflozin (Jardiance), Dapagliflozin + Metformin XR (Xigduo). conditions: Chronic Hepatitis B studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 412 type: ESTIMATED name: Dapagliflozin 10mg Tab name: Placebo 10mg Tab measure: The primary endpoint is liver complications measure: Cardiovascular complications measure: change in liver stiffness measurement measure: change anthropometric parameters measure: change anthropometric parameters sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prince of Wales Hospital status: RECRUITING city: Hong Kong country: Hong Kong name: Angel ML Chim, MSc role: CONTACT phone: 26324205 email: angelchim@cuhk.edu.hk name: Grace LH Wong, MD role: CONTACT phone: +85235053538 email: wonglaihung@cuhk.edu.hk lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06364917 id: IRB-300012781 (UAB2432) briefTitle: DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2027-01-30 date: 2027-06 date: 2024-04-15 date: 2024-04-26 name: University of Alabama at Birmingham class: OTHER briefSummary: The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This study will help us understand if using two types of immune therapy together with chemotherapy is better than using one type of immune therapy with chemotherapy. We're doing this by looking at changes in the subject's cancer's DNA in the blood after starting treatment. conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Pembrolizumab name: Carboplatin name: Paclitaxel name: Pemetrexed name: Nivolumab name: Ipilimumab measure: Rate of Molecular Response in Patients with PD-L1 Negative Advanced NSCLC Treated with Dual vs. Single ICB Plus CT Regimens measure: Efficacy Evaluation measure: Correlation Analysis measure: Progression-Free Survival (PFS) measure: Median Overall Survival (OS) measure: Tolerability Assessment sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Margaret Thomas, MPH role: CONTACT email: margaretannthomas@uabmc.edu name: Aakash Desai, MD role: PRINCIPAL_INVESTIGATOR name: Maya Khalil, MD role: SUB_INVESTIGATOR name: Yanish Boumber, MD role: SUB_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06364904 id: SYSKY-2024-123-02 briefTitle: An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-04-15 date: 2029-04-15 date: 2024-04-15 date: 2024-04-15 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 210 type: ESTIMATED name: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib name: Tislelizumab, Cisplatin, Gemcitabine measure: Progression-Free Survival(PFS) measure: Incidence of Grade 3/4 Neutropenia measure: ORR measure: overall survival (OS) measure: Safety and AE measure: Disease Control Rate(DCR) measure: During Of Response(DOR) measure: Biomarker Endpoint Analyses sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang Hospital, Southern Medical University city: Guangzhou state: Guangdong country: China name: Fan Wu, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Sun Yat-sen Memorial Hospital city: Guangzhou state: Guangdong country: China name: Wenlong Zhong, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: The First Affiliated Hospital of Sun Yat-sen University city: Guangzhou state: Guangdong country: China name: Junxin Chen, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: The Third Affiliated Hospital of Sun Yat-sen University city: Guangzhou state: Guangdong country: China name: Yun Luo, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Zhujiang Hospital of Southern Medical University city: Guangzhou state: Guangdong country: China name: Ebai Xu, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology city: Wuhan state: Hubei country: China name: Zheng Liu, Ph.D role: CONTACT lat: 30.58333 lon: 114.26667 facility: Hunan Cancer Hospital city: Changsha state: Hunan country: China name: Yu Xie, Ph.D role: CONTACT lat: 28.19874 lon: 112.97087 facility: Xiangya Hospital, Central South University city: Changsha state: Hunan country: China name: Xiongbing Zu, Ph.D role: CONTACT lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06364891 id: VMMC NEXUS briefTitle: Assessing the Impact of a Digital VMMC Platform acronym: VMMC NEXUS overallStatus: RECRUITING date: 2023-10-01 date: 2024-12-31 date: 2024-12-31 date: 2024-04-15 date: 2024-04-15 name: University of Alabama at Birmingham class: OTHER name: Centre for Infectious Disease Research in Zambia briefSummary: VMMC has been identified as a crucial intervention by UNAIDS to achieve the 2030 global target of a 90% reduction in new HIV infections compared with 2010 levels. CIDRZ, a key partner to the Ministry of Health, has worked with DesireLine to develop a mobile application that supports mobilisers to segment potential clients and provide them with targeted messaging based on their segmentation type. The hypothesis of our proposed study is that targeted interventions addressing the barriers for each of the seven segments, assisted by the Digital Mobilization Tool, will better meet the needs of potential clients and therefore improve uptake of VMMC services, specifically among the three most-resistant segments.
* Develop a workplan to enable national and regional scale-up of the mobilization model and NEXUS Digital Mobilization Tool if demonstrated as effective conditions: Voluntary Medical Male Circumcision studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Cluster randomised control study primaryPurpose: OTHER masking: NONE count: 2000 type: ESTIMATED name: VMMC NEXUS Digital application measure: Total number of VMMC's conducted in intervention vs control measure: Total number of VMMC's by segment measure: Total number of VMMC's by age measure: Costing measure: Process evaluation measure: Develop a workplan and handbook to allow for the intervention to be scaled up elsewhere. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ministry of Health facilities status: RECRUITING city: Lusaka zip: 10101 country: Zambia name: Carolyn Moore role: CONTACT phone: 0966841034 email: carolyn.bolton@cidrz.org lat: -15.40669 lon: 28.28713 hasResults: False
nctId: NCT06364878 id: 813533 briefTitle: Non-invasive Diagnostics of Microbial Keratitis overallStatus: RECRUITING date: 2023-08-23 date: 2025-03-01 date: 2028-04-08 date: 2024-04-15 date: 2024-04-15 name: Sorlandet Hospital HF class: OTHER_GOV briefSummary: Infectious keratitis is a significant cause of partial vision loss and blindness and places a large burden on eye care professionals. One of the main challenges for the ophthalmologist when presented with a case of suspected microbial keratitis is the determination of the subtype of keratitis. It must be determined whether the origin of the infection is bacterial, viral, fungal, or parasitic, in order to prescribe a correct, effective treatment aimed at the causative pathogen. In daily practice this can be challenging, and general treatments with antibiotics are prescribed. Some cases then experiences deterioration, resulting in more patients visits and further rounds of invasive treatments and progressive vision deterioration.
This project is designed to break this cycle of nonspecific diagnosis, suboptimal treatment, and progressive worsening of vision with increased interventions. New, advanced diagnostics will be brought into the clinic to provide additional information which, if our hypothesis is correct, will result in more rapid and accurate diagnosis of the keratitis subtype. This will translate into earlier administration of a more targeted treatment, avoiding the repeated round of non-targeted treatment and progressive worsening of the patient's vision. This can directly reduce to number of clinic visits and specialist time required for treatment and follow-up of keratitis, knowledge of how the eye responds to various microbes by initiating a specific cascade of molecular inflammatory signals and changes in protein expression in the tear film.
Using in vivo confocal microscopy (IVCM) we will document the cellular status of the cornea and identify microbes infecting the cornea in real-time. Secondly, tear samples will be obtained from patients with keratitis to evaluate and quantify the molecular cytokine signatures associated with specific microbial species, confirmed by microbiological culture. We will for the first time develop cytokine profiles for the various types of infection, identifying diagnostic cytokines which in the longer term can lead to development of rapid point-of-care biomarker diagnostics.
H2: Cytokine profiles (or a subset of molecules) in the eye are specific for viral, bacterial, fungal, or amoebic keratitis; and H3: A combination of in vivo confocal microscopy and molecular profiling of the tear film can yield a specific keratitis diagnosis closely matching the clinical progression and outcome of keratitis. conditions: Infectious Keratitis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 125 type: ESTIMATED name: In vivo confocal microscopy name: Tear film sampling measure: IVCM findings and cytokine profile in infectious keratitis is specific for the different microbial subtypes. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sorlandet hospital status: RECRUITING city: Arendal country: Norway name: Neil Lagali role: CONTACT lat: 58.46151 lon: 8.77253 hasResults: False
nctId: NCT06364865 id: 2022-04 briefTitle: AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study acronym: AE05ML overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-01-31 date: 2025-03-30 date: 2024-04-15 date: 2024-04-16 name: Teleflex class: INDUSTRY briefSummary: This clinical registry study aims to evaluate the safety and effectiveness of the AE05ML device for ligating vessels and tissue structures during laparoscopic surgery using Hem-o-lok® Medium Large (ML) polymer clips. The primary objective is to assess the device's safety and performance, with secondary objectives focusing on device performance characteristics and operator feedback. conditions: Gall Bladder Disease conditions: Bile Duct Diseases conditions: Acute Cholecystitis conditions: Kidney conditions: Liver conditions: Appendix conditions: Spleen Disease conditions: Prostate studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 161 type: ESTIMATED name: laparoscopic procedure measure: Evaluating the safety of AE05ML measure: Evaluating the performance of AE05ML measure: Evaluating device performance characteristics measure: Evaluating operator reported feedback sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364852 id: LY007C1101 briefTitle: An Evaluation of LY007 Cell Injection for r/r B-NHL acronym: r/r B-NHL overallStatus: RECRUITING date: 2021-12-25 date: 2024-08-31 date: 2026-05-31 date: 2024-04-15 date: 2024-04-15 name: Ruijin Hospital class: OTHER name: The First Affiliated Hospital with Nanjing Medical University name: Shanghai Longyao Biotechnology Inc., Ltd. briefSummary: An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research conditions: B-NHL studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: LY007 measure: Maximum tolerated dose or clinically recommended dose; measure: Dose limiting toxicity measure: Adverse Events , Serious Adverse Events , Adverse Events of Particular Concern, Including cytokine release syndrome , neurotoxicity,physical examination, vital signs, ECOG score, ECG, laboratory testing, etc. measure: PK aspect measure: PK aspect measure: PD aspect measure: therapeutic effect measure: Anti LY007 antibody measure: The titer of human anti mouse antibody measure: Exploratory study endpoint sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ruijin hospital status: RECRUITING city: Shanghai country: China name: Weili Zhao, MD role: CONTACT phone: 13512112076 phoneExt: 610707 email: zwl_trial@163.com name: Zixun Yan, MD role: CONTACT phone: +8613482056727 phoneExt: 610707 email: yanzixun125@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06364839 id: CT2024-ZJU-OBS7 briefTitle: Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases overallStatus: COMPLETED date: 2024-02-20 date: 2024-03-23 date: 2024-03-25 date: 2024-04-15 date: 2024-04-15 name: Xiao Xu class: OTHER briefSummary: Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis. Here we aim to investigate the prognosis of non-cirrhosis HCC recipients, expecting to provide theoretical basis for further improvement of these patients.
Methods: This retrospective study analyze outcomes between adult HCC recipients arising in non-cirrhotic and cirrhotic liver from two national databases (CLTR and UNOS, January 2015 to December 2020). Based on important variables, 1:2 and 1:1 propensity score matching (PSM) were performed respectively. conditions: Hepatocellular Carcinoma, Non-cirrhotic Liver studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1 type: ACTUAL measure: Postoperative complications were evaluated by postoperative imaging and serological examination measure: The overall survival rate was evaluated by follow-up investigation and outpatient review measure: The tumor-free survival rate was evaluated by follow-up investigation and outpatient review sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Xiao Xu city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06364826 id: NPC-202403 briefTitle: Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2026-04-22 date: 2026-04-22 date: 2024-04-15 date: 2024-04-15 name: Zhejiang Cancer Hospital class: OTHER briefSummary: This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles. conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Sintilimab, bevacizumab, gemcitabine name: IMRT measure: 3-year Event-free survival rate measure: Objective Response Rate measure: Disease Control Rate measure: Progression-Free Survival measure: Overall survival measure: adverse events(AEs) measure: biomarkers sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False